Galera.jpg
Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease
18 mai 2020 16h05 HE | Galera Therapeutics
MALVERN, Pa., May 18, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera.jpg
Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to be Presented at ASCO 2020 Virtual Scientific Program
13 mai 2020 17h19 HE | Galera Therapeutics
MALVERN, Pa., May 13, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera.jpg
Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
12 mai 2020 07h00 HE | Galera Therapeutics
ROMAN Phase 3 Trial Topline Data Readout Guidance Updated to 2H21 Due to Impact of COVID-19 Amendment to Royalty Agreement for Additional $37.5M Extends Cash Runway into 2H22 Locally Advanced...
Galera.jpg
Galera Therapeutics to Present at BofA Securities 2020 Health Care Conference
05 mai 2020 08h00 HE | Galera Therapeutics
MALVERN, Pa., May 05, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera.jpg
Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program
30 avr. 2020 16h15 HE | Galera Therapeutics
MALVERN, Penn., April 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera.jpg
Galera Therapeutics Appoints Linda B. West to Board of Directors
02 avr. 2020 08h00 HE | Galera Therapeutics
MALVERN, Pa., April 02, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera.jpg
Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments
10 mars 2020 07h00 HE | Galera Therapeutics
- Expanded Lead Product Candidate Avasopasem Manganese into Second Radiation Toxicity Indication - - Presented Data Demonstrating Avasopasem Manganese Maintained Anti-Cancer Benefit of...
Galera.jpg
Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral Mucositis
27 févr. 2020 16h05 HE | Galera Therapeutics
MALVERN, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera.jpg
Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data at 2020 Multidisciplinary Head and Neck Cancers Symposium
24 févr. 2020 08h00 HE | Galera Therapeutics
MALVERN, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...
Galera.jpg
Galera Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
19 févr. 2020 08h00 HE | Galera Therapeutics
MALVERN, Pa., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel,...